“ The Company has committed to repeating the stu
Post# of 149951
(Total Views: 447)
Posted On: 02/05/2025 12:07:35 AM
“ The Company has committed to repeating the study based on unpublished observations by Dr. Pestell’s lab and will now employ a treatment sequence involving temozolomide and leronlimab. This follow-up study will start immediately and should help clarify the potential therapeutic benefit of leronlimab in the treatment of GBM.”
Investors Hangout: https://investorshangout.com/post/view?id=674...z8zMAkj2BU
Investors Hangout: https://investorshangout.com/post/view?id=674...z8zMAkj2BU
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼